{"title":"Pfizer Collaborates with Nodality to Streamline Autoimmune Disease Drug Development","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I8.1790","DOIUrl":null,"url":null,"abstract":"Pfizer has formed a multiyear collaboration with Nodality to use the latter’s single cell network profiling (SCNP) technology as a tool to streamline the development of new compounds for autoimmune diseases, beginning with lupus. Pfizer also has the option to use Nodality's technology, which was licensed from Stanford University, to develop novel companion diagnostics. Pfizer Venture Investments has been an investor in Nodality since 2008.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"16 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I8.1790","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Pfizer has formed a multiyear collaboration with Nodality to use the latter’s single cell network profiling (SCNP) technology as a tool to streamline the development of new compounds for autoimmune diseases, beginning with lupus. Pfizer also has the option to use Nodality's technology, which was licensed from Stanford University, to develop novel companion diagnostics. Pfizer Venture Investments has been an investor in Nodality since 2008.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
